Hep C.
Seems this company is just stringing along investors. All things considered, they will be delisted from NASDAQ soon. It really is a shame, excusing management for questionable decisions over the last 4 years. This could have been a nice co-treatment with SOC IFN.
Rev: CELG
Secondary Cancers.
More to come.
Wednesday, August 31, 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment